Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription

Articles published in Ann Oncol

Retrieve available abstracts of 67 articles:
HTML format

Single Articles

    December 2021
  1. WAUTERS E, Vansteenkiste J
    Acquired resistance in NSCLC: the journey from clinical definition to molecular understanding.
    Ann Oncol. 2021;32:1463-1465.

  2. TOPP BG, Thiagarajan K, De Alwis DP, Snyder A, et al
    Lesion-level heterogeneity of radiologic progression in patients treated with pembrolizumab.
    Ann Oncol. 2021;32:1618-1625.
    PubMed     Abstract available

    November 2021
  3. ATTILI I, Passaro A, de Marinis F
    Anti-TIGIT to overcome resistance to immune checkpoint inhibitors in lung cancer: limits and potentials.
    Ann Oncol. 2021 Nov 25. pii: S0923-7534(21)04823.

  4. NIU J, Maurice-Dror C, Lee DH, Kim DW, et al
    First-in-human phase 1 study of the anti-TIGIT antibody vibostolimab as monotherapy or with pembrolizumab for advanced solid tumors, including non-small cell lung cancer.
    Ann Oncol. 2021 Nov 17. pii: S0923-7534(21)04776.
    PubMed     Abstract available

    October 2021
  5. CHOW A, Hellmann MD
    Insights from prospective multi-omic profiling of lymphocytes in resected lung cancer.
    Ann Oncol. 2021 Oct 26. pii: S0923-7534(21)04549.

  6. FEDERICO L, McGrail DJ, Bentebibel SE, Haymaker C, et al
    Distinct tumor-infiltrating lymphocyte landscapes are associated with clinical outcomes in localized non-small cell lung cancer.
    Ann Oncol. 2021 Oct 12. pii: S0923-7534(21)04519.
    PubMed     Abstract available

  7. NOVELLO S, Torri V, Grohe C, Kurz S, et al
    International Tailored Chemotherapy Adjuvant (ITACA) Trial, a Phase III Multicenter Randomized Trial Comparing Adjuvant Pharmacogenomic-Driven Chemotherapy versus Standard Adjuvant Chemotherapy in completely Resected Stage II-IIIA Non-Small Cell Lung
    Ann Oncol. 2021 Oct 5. pii: S0923-7534(21)04496.
    PubMed     Abstract available

  8. SHITARA K, Lunceford J
    Response to the letter to the Editor: TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061.
    Ann Oncol. 2021;32:1303-1304.

    September 2021
  9. PETERS S, Pujol JL, Dafni U, Domine M, et al
    Consolidation nivolumab and ipilimumab versus observation in limited-disease small cell lung cancer after chemo-radiotherapy - Results from the randomised phase II ETOP/IFCT 4-12 STIMULI trial.
    Ann Oncol. 2021 Sep 22. pii: S0923-7534(21)04490.
    PubMed     Abstract available

  10. DICKSON JL, Horst C, Nair A, Tisi S, et al
    Hesitancy around low dose CT screening for lung cancer.
    Ann Oncol. 2021 Sep 20. pii: S0923-7534(21)04487.
    PubMed     Abstract available

  11. SCHOENFELD AJ, Antonia SJ, Awad MM, Felip E, et al
    Clinical definition of acquired resistance to immunotherapy in patients with metastatic non-small cell lung cancer.
    Ann Oncol. 2021 Sep 3. pii: S0923-7534(21)04455.
    PubMed     Abstract available

  12. SAW SPL, Tan DSW
    Co-targeting the VEGF axis and immune checkpoints in NSCLC: back to the future.
    Ann Oncol. 2021;32:1075-1076.

  13. FOOTE MB, Maron SB, Cercek A, Argiles G, et al
    TMB cut-offs fail to predict benefit of PD-1 blockade in gastroesophageal adenocarcinoma in KEYNOTE-061.
    Ann Oncol. 2021;32:1188-1189.

    August 2021
  14. REMON J, Soria JC, Peters S
    Early and locally advanced non-small-cell lung cancer: an update of the ESMO Clinical Practice Guidelines focusing on diagnosis, staging, systemic and local therapy.
    Ann Oncol. 2021 Aug 28. pii: S0923-7534(21)04279.

  15. CORTELLINI A, Ricciuti B, Facchinetti F, Alessi JVM, et al
    Antibiotic-exposed patients with non-small cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy.
    Ann Oncol. 2021 Aug 13. pii: S0923-7534(21)03973.
    PubMed     Abstract available

    July 2021
  16. RODRIGUEZ-ABREU D, Powell SF, Hochmair MJ, Gadgeel S, et al
    Pemetrexed plus platinum with or without pembrolizumab in patients with previously untreated metastatic nonsquamous NSCLC: protocol-specified final analysis from KEYNOTE-189.
    Ann Oncol. 2021;32:881-895.
    PubMed     Abstract available

    June 2021
  17. SUGAWARA S, Lee JS, Kang JH, Kim HR, et al
    Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced non-squamous non-small cell lung cancer.
    Ann Oncol. 2021 Jun 14. pii: S0923-7534(21)02052.
    PubMed     Abstract available

  18. RECK M, Carbone DP, Garassino M, Barlesi F, et al
    Targeting KRAS in non-small cell lung cancer: recent progress and new approaches.
    Ann Oncol. 2021 Jun 2. pii: S0923-7534(21)02045.
    PubMed     Abstract available

  19. BARDIA A, Messersmith WA, Kio EA, Berlin JD, et al
    Sacituzumab govitecan, a Trop-2-directed antibody-drug conjugate, for patients with epithelial cancer: final safety and efficacy results from the phase I/II IMMU-132-01 basket trial.
    Ann Oncol. 2021;32:746-756.
    PubMed     Abstract available

    May 2021
    Reframing recalcitrance for small cell lung cancer.
    Ann Oncol. 2021 May 3. pii: S0923-7534(21)01186.

  21. LACH KD, Sorin M, Huynh C, Alirezaie NS, et al
    Combined small-cell lung carcinoma revealed to be an intratumoural metastasis by genetic analysis.
    Ann Oncol. 2021;32:679-681.

    April 2021
  22. DINGEMANS AC, Fruh M, Ardizzoni A, Besse B, et al
    Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(dagger).
    Ann Oncol. 2021 Apr 9. pii: S0923-7534(21)01113.

  23. SHI Y, Wu L, Yu X, Xing P, et al
    Retraction notice to "30MO ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC)": [Annals of Oncology Volume 31, Supplement 7, Decemb
    Ann Oncol. 2021;32:576.
    PubMed     Abstract available

  24. BAUDIN E, Caplin M, Garcia-Carbonero R, Fazio N, et al
    Lung and thymic carcinoids: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up().
    Ann Oncol. 2021;32:439-451.

    March 2021
    EDITORIAL Lorlatinib in the treatment of anaplastic lymphoma kinase positive non-small-cell lung cancer.
    Ann Oncol. 2021 Mar 16. pii: S0923-7534(21)00876.

  26. REMON J, Aldea M, Besse B, Planchard D, et al
    Small cell lung cancer: a slightly less orphan disease after immunotherapy.
    Ann Oncol. 2021 Mar 15. pii: S0923-7534(21)00877.
    PubMed     Abstract available

  27. SZNOL M, Melero I
    Revisiting anti-CTLA-4 antibodies in combination with PD-1 blockade for cancer immunotherapy.
    Ann Oncol. 2021;32:295-297.

    February 2021
  28. FELIP E, Shaw AT, Bearz A, Camidge DR, et al
    Intracranial and extracranial efficacy of lorlatinib in patients with ALK-positive non-small-cell lung cancer previously treated with second-generation ALK TKIs.
    Ann Oncol. 2021 Feb 24. pii: S0923-7534(21)00129.
    PubMed     Abstract available

  29. SUBBIAH V, Shen T, Tetzlaff M, Weissferdt A, et al
    Patient-driven discovery and post-clinical validation of NTRK3 fusion as an acquired resistance mechanism to selpercatinib in RET fusion-positive lung cancer.
    Ann Oncol. 2021 Feb 19. pii: S0923-7534(21)00127.

  30. SPIGEL DR, Vicente D, Ciuleanu TE, Gettinger S, et al
    Second-Line Nivolumab in Relapsed Small-Cell Lung Cancer: CheckMate 331.
    Ann Oncol. 2021 Feb 1. pii: S0923-7534(21)00099.
    PubMed     Abstract available

  31. SUBBIAH V, Shen T, Terzyan SS, Liu X, et al
    Structural basis of acquired resistance to selpercatinib and pralsetinib mediated by non-gatekeeper RET mutations.
    Ann Oncol. 2021;32:261-268.
    PubMed     Abstract available

  32. SATURNO G, Lopes F, Niculescu-Duvaz I, Niculescu-Duvaz D, et al
    The paradox-breaking panRAF plus SRC family kinase inhibitor, CCT3833, is effective in mutant KRAS-driven cancers.
    Ann Oncol. 2021;32:269-278.
    PubMed     Abstract available

    January 2021
  33. CARIOLI G, Malvezzi M, Bertuccio P, Boffetta P, et al
    European cancer mortality predictions for the year 2021 with focus on pancreatic and female lung cancer.
    Ann Oncol. 2021 Jan 21. pii: S0923-7534(21)00014.
    PubMed     Abstract available

  34. HILTBRUNNER S, Britschgi C, Schuberth P, Bankel L, et al
    Local delivery of CAR T cells targeting fibroblast activation protein is safe in patients with pleural mesothelioma: first report of FAPME, a phase I clinical trial.
    Ann Oncol. 2021;32:120-121.

    December 2020
  35. PERETS R, Bar J, Rasco DW, Ahn MJ, et al
    Safety and Efficacy of Quavonlimab, a Novel Anti-CTLA-4 Antibody (MK-1308), in Combination with Pembrolizumab in First-Line Advanced Non-Small Cell Lung Cancer.
    Ann Oncol. 2020 Dec 1. pii: S0923-7534(20)43175.
    PubMed     Abstract available

  36. SHAVERDIAN N, Beattie J, Thor M, Offin M, et al
    Safety of thoracic radiotherapy in patients with prior immune-related adverse events from immune checkpoint inhibitors.
    Ann Oncol. 2020;31:1719-1724.
    PubMed     Abstract available

  37. POPAT S, Curioni-Fontecedro A, Dafni U, Shah R, et al
    A multicentre randomised phase III trial comparing pembrolizumab versus single-agent chemotherapy for advanced pre-treated malignant pleural mesothelioma: the European Thoracic Oncology Platform (ETOP 9-15) PROMISE-meso trial.
    Ann Oncol. 2020;31:1734-1745.
    PubMed     Abstract available

  38. LASKIN J, Liu SV, Tolba K, Heining C, et al
    NRG1 fusion-driven tumors: biology, detection, and the therapeutic role of afatinib and other ErbB-targeting agents.
    Ann Oncol. 2020;31:1693-1703.
    PubMed     Abstract available

  39. MARINELLI D, Mazzotta M, Scalera S, Terrenato I, et al
    KEAP1-driven co-mutations in lung adenocarcinoma unresponsive to immunotherapy despite high tumor mutational burden.
    Ann Oncol. 2020;31:1746-1754.
    PubMed     Abstract available

  40. SHI Y, Wu L, Yu X, Xing P, et al
    RETRACTED: ORIENT-3: A randomized, open-label, phase III study of sintilimab versus docetaxel in previously treated advanced/metastatic squamous non-small cell lung cancer (sqNSCLC).
    Ann Oncol. 2020;31 Suppl 7:S1428.
    PubMed     Abstract available

    November 2020
  41. JEE J, Li BT
    Expanding the nanotherapeutic toolbox for non-small-cell lung cancer.
    Ann Oncol. 2020 Nov 22. pii: S0923-7534(20)43165.

    Osimertinib versus platinum-pemetrexed for patients with EGFR T790M advanced NSCLC and progression on a prior EGFR-tyrosine kinase inhibitor: AURA3 overall survival analysis.
    Ann Oncol. 2020;31:1536-1544.
    PubMed     Abstract available

  43. MOSELE F, Remon J, Mateo J, Westphalen CB, et al
    Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group.
    Ann Oncol. 2020;31:1491-1505.
    PubMed     Abstract available

  44. BECKER T, Weberpals J, Jegg AM, So WV, et al
    An enhanced prognostic score for overall survival of patients with cancer derived from a large real-world cohort.
    Ann Oncol. 2020;31:1561-1568.
    PubMed     Abstract available

    October 2020
  45. SHI M, Gu A, Tu H, Huang C, et al
    Comparing Nanoparticle Polymeric Micellar Paclitaxel and Solvent-based Paclitaxel as First-line Treatment of Advanced Non-Small Cell Lung Cancer: An Open-label, Randomized, Multicenter, Phase III Trial.
    Ann Oncol. 2020 Oct 29. pii: S0923-7534(20)42982.
    PubMed     Abstract available

  46. TAN L, Solomon BJ
    Defining Resistance Mechanisms to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer (editorial re: Lin et al.).
    Ann Oncol. 2020 Oct 9. pii: S0923-7534(20)42493.

    September 2020
  47. LIN JJ, Liu SV, McCoach CE, Zhu VW, et al
    Mechanisms of Resistance to Selective RET Tyrosine Kinase Inhibitors in RET Fusion-Positive Non-Small Cell Lung Cancer.
    Ann Oncol. 2020 Sep 29. pii: S0923-7534(20)42465.
    PubMed     Abstract available

  48. VAN DE GARDE EMW, van Bedaf LR, Hurkmans DP, van den Heuvel MM, et al
    Antibiotic use and reduced effectiveness of second-line immunotherapy for lung cancer: all the time or just at the start of treatment?
    Ann Oncol. 2020 Sep 22. pii: S0923-7534(20)42457.

  49. PARK S, Ahn MJ
    Osimertinib in CNS progressive EGFR-mutant lung cancer: Do we need to detect T790M?
    Ann Oncol. 2020 Sep 2. pii: S0923-7534(20)42316.

    August 2020
  50. FACCHINETTI F, Leonetti A, Tiseo M
    Osimertinib in CNS-progressive EGFR-mutant lung cancer: Do we need to detect T790M?
    Ann Oncol. 2020 Aug 13. pii: S0923-7534(20)42060.

    July 2020
  51. PARK S, Lee MH, Seong M, Kim ST, et al
    A phase II, multicenter, two cohort study of 160 mg osimertinib in EGFR T790M-positive non-small cell lung cancer patients with brain metastases or leptomeningeal disease who progressed on prior EGFR TKI therapy.
    Ann Oncol. 2020 Jul 4. pii: S0923-7534(20)39927.
    PubMed     Abstract available

    June 2020
  52. LUO J, Rizvi H, Preeshagul IR, Egger JV, et al
    COVID-19 in patients with lung cancer.
    Ann Oncol. 2020 Jun 16. pii: S0923-7534(20)39894.
    PubMed     Abstract available

    Recent eUpdate to the ESMO Clinical Practice Guidelines on early and locally advanced non-small-cell lung cancer (NSCLC).
    Ann Oncol. 2020 Jun 2. pii: S0923-7534(20)39865.

  54. QU J, Yang R, Song L, Kamel IR, et al
    Atypical lung feature on chest CT in a lung adenocarcinoma cancer patient infected with COVID-19.
    Ann Oncol. 2020;31:825-826.

    May 2020
  55. MOK T, Camidge DR, Gadgeel SM, Rosell R, et al
    TEMPORARY REMOVAL: Updated overall survival and final progression-free survival data for patients with treatment-naive advanced ALK-positive non-small-cell lung cancer in the ALEX study.
    Ann Oncol. 2020 May 11. pii: S0923-7534(20)39796.
    PubMed     Abstract available

  56. CARIOLI G, Bertuccio P, Boffetta P, Levi F, et al
    European cancer mortality predictions for the year 2020 with a focus on prostate cancer.
    Ann Oncol. 2020;31:650-658.
    PubMed     Abstract available

  57. SCHOENFELD AJ, Rizvi H, Bandlamudi C, Sauter JL, et al
    Clinical and molecular correlates of PD-L1 expression in patients with lung adenocarcinomas.
    Ann Oncol. 2020;31:599-608.
    PubMed     Abstract available

    April 2020
  58. SHIM JH, Kim HS, Cha H, Kim S, et al
    HLA-corrected tumor mutation burden and homologous recombination deficiency for the prediction of response to PD-(L)1 blockade in advanced non-small-cell lung cancer patients.
    Ann Oncol. 2020 Apr 19. pii: S0923-7534(20)39295.
    PubMed     Abstract available

  59. PASSARO A, Peters S, Mok TSK, Attili I, et al
    Testing for COVID-19 in lung cancer patients.
    Ann Oncol. 2020 Apr 9. pii: S0923-7534(20)39293.

  60. LIN G, Li C, Li PS, Fang WZ, et al
    Genomic origin and EGFR-TKI treatments of pulmonary adenosquamous carcinoma.
    Ann Oncol. 2020;31:517-524.
    PubMed     Abstract available

  61. HE Q, Shi X, Zhu H, Yan J, et al
    A case treated with Crizotinib after secondary MET amplification of A double Rare L747S and G719S EGFR mutation Pulmonary Sarcomatoid Carcinoma.
    Ann Oncol. 2020;31:544-546.

  62. PANJE CM, Lupatsch JE, Barbier M, Pardo E, et al
    A cost-effectiveness analysis of consolidation immunotherapy with durvalumab in stage III NSCLC responding to definitive radiochemotherapy in Switzerland.
    Ann Oncol. 2020;31:501-506.
    PubMed     Abstract available

  63. METAXAS Y, Fruh M, Eboulet EI, Grosso F, et al
    Lurbinectedin as second- or third-line palliative therapy in malignant pleural mesothelioma: an international, multi-centre, single-arm, phase II trial (SAKK 17/16).
    Ann Oncol. 2020;31:495-500.
    PubMed     Abstract available

    March 2020
  64. SCHULER M, Berardi R, Lim WT, de Jonge M, et al
    Molecular correlates of response to capmatinib in advanced non-small-cell lung cancer: clinical and biomarker results from a Phase I trial.
    Ann Oncol. 2020 Mar 30. pii: S0923-7534(20)36380.
    PubMed     Abstract available

  65. MAZZOTTA M, Filetti M, Rossi A, Roberto M, et al
    Is there a place for crizotinib in c-MET alterations? A case of efficacy in ALK positive NSCLC patient with secondary c-MET amplification.
    Ann Oncol. 2020;31:440-441.

    February 2020
  66. ZHAI H, Moore D, Jamal-Hanjani M
    Inactivation of RB1 and histological transformation in EGFR-mutant lung adenocarcinoma.
    Ann Oncol. 2020;31:169-170.

  67. ZHAO X, Shen J, Ivaturi V, Gopalakrishnan M, et al
    Model-based evaluation of the efficacy and safety of nivolumab once every 4 weeks across multiple tumor types.
    Ann Oncol. 2020;31:302-309.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.